Key facts
- This page summarizes Dawn Giangiulio's Form 3 filing for Design Therapeutics, Inc. (DSGN).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 17 Aug 2021, 19:21.
Dawn Giangiulio - 13 Aug 2021 Form 3 Insider Report for Design Therapeutics, Inc. (DSGN)
- Reporting relationship
- Principal Accounting Officer
- Issuer ticker
- DSGN
- Reported as of
- 13 Aug 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ Mustapha Parekh, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Dawn Giangiulio filed Form 3 for Design Therapeutics, Inc. (DSGN) on 17 Aug 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DSGN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 7,500
- Date
- 13 Aug 2021
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DSGN
holding
Derivative
Stock option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 13 Aug 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,269
- Exercise price
- $0.9500
- Footnotes
- F1
DSGN
holding
Derivative
Stock option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 13 Aug 2021
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 24,539
- Exercise price
- $0.9500
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
25% of the shares vested on March 30, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter.
Footnote F2
25% of the shares shall vest on December 7, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter.